{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:06:46Z","timestamp":1792048006038,"version":"4.4.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Cerebrospinal fluid (CSF) biomarkers are currently the only clinically validated biofluid diagnostic test for Alzheimer\u2019s Disease (AD) available in Australia. Testing of CSF biomarkers via lumbar puncture (LP), including quantification of amyloid-\u03b2 peptide, total tau protein, and phosphorylated tau, can give insight into underlying pathophysiological changes and provide greater certainty in confirming or excluding the presence of Alzheimer\u2019s disease changes compared to standard clinical and radiological assessments. Despite CSF analysis being a safe and cost-effective diagnostic method, the use of CSF biomarkers in the evaluation of potential AD remains limited in Australian clinical practice due to a variety of factors, including regional access challenges, concerns over the perceived invasiveness of LP and a lack of confidence among clinicians in interpreting the results. The advent of disease-modifying therapies as a potential new treatment strategy to reduce the rate of progression in people with AD will drive the demand for early diagnosis of AD. This perspective argues for broader adoption of CSF biomarker testing by providing evidence-based, clinically informed expert guidance on when and why to consider CSF biomarker testing.<\/jats:p>","DOI":"10.3389\/fpsyt.2024.1488494","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T14:40:41Z","timestamp":1733409641000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Using cerebrospinal fluid biomarkers to diagnose Alzheimer\u2019s disease: an Australian perspective"],"prefix":"10.3389","volume":"15","author":[{"given":"Dhamidhu","family":"Eratne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Nestor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimity","family":"Pond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Velakoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin L.","family":"Masters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"B1","unstructured":"Dementia in Australia. Web Report\n          \n          2023"},{"key":"B2","unstructured":"Early diagnosis of dementia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2147\/DNND.S228939","article-title":"Alzheimer's disease: why we need early diagnosis","volume":"9","author":"Rasmussen","year":"2019","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170680","article-title":"Cerebrospinal fluid biomarkers for early and differential Alzheimer's disease diagnosis","volume":"62","author":"Bjerke","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e12314","DOI":"10.1002\/dad2.12314","article-title":"Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios","volume":"14","author":"Bouwman","year":"2022","journal-title":"Alzheimers Dement (Amst)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-215432","article-title":"Lights and shadows of cerebrospinal fluid biomarkers in the current Alzheimer's disease framework","volume":"86","author":"Gallucci","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer\u2019s Dementia"},{"key":"B10","doi-asserted-by":"publisher","first-page":"8598","DOI":"10.3390\/ijms23158598","article-title":"Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: the role of CSF biomarkers during the evolution of diagnostic criteria","volume":"23","author":"Dulewicz","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12316","article-title":"The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid \u03b2 and tau","volume":"17","author":"Hansson","year":"2021","journal-title":"Alzheimers Dement"},{"key":"B12","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3390\/diagnostics10050326","article-title":"Role of body-fluid biomarkers in Alzheimer's disease diagnosis","volume":"10","author":"Nguyen","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13195-016-0192-z","article-title":"Utility of CSF biomarkers in psychiatric disorders: a national multicenter prospective study","volume":"8","author":"Paquet","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.07.220","article-title":"Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease","volume":"14","author":"Shaw","year":"2018","journal-title":"Alzheimers Dement"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-329530","article-title":"Clinical utility of cerebrospinal fluid biomarkers in the evaluation of cognitive impairment: a systematic review and meta-analysis","volume":"94","author":"Hazan","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13024-021-00430-x","article-title":"Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics","volume":"16","author":"Zetterberg","year":"2021","journal-title":"Mol Neurodegener"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afy004","article-title":"The role of biomarkers and imaging in the clinical diagnosis of dementia","volume":"47","author":"Bayer","year":"2018","journal-title":"Age Ageing"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awl269","article-title":"CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer\u2019s disease","volume":"129","author":"Buerger","year":"2006","journal-title":"Brain"},{"key":"B19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2217\/bmm.09.83","article-title":"Cerebrospinal fluid biomarkers of Alzheimer's disease","volume":"4","author":"Fagan","year":"2010","journal-title":"biomark Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12000","article-title":"Concordance of Lumipulse cerebrospinal fluid t-tau\/Abeta42 ratio with amyloid PET status","volume":"16","author":"Kaplow","year":"2020","journal-title":"Alzheimers Dement"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/1039856218762308","article-title":"Alzheimer\u2019s disease: clinical update on epidemiology, pathophysiology and diagnosis","volume":"26","author":"Eratne","year":"2018","journal-title":"Australas Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170773","article-title":"The past and the future of Alzheimer's disease fluid biomarkers","volume":"62","author":"Blennow","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026380","article-title":"What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France","volume":"9","author":"Cognat","year":"2019","journal-title":"BMJ Open"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12372","article-title":"State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease","volume":"18","author":"Hampel","year":"2022","journal-title":"Alzheimer's Dement"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/alz.v18.11","article-title":"Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer\u2019s disease and frontotemporal disorders in clinical settings","volume":"18","author":"Eratne","year":"2022","journal-title":"Alzheimer\u2019s Dementia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12724","article-title":"Plasma A\u03b242\/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer\u2019s disease continuum: A cross-sectional and longitudinal study in the AIBL cohort","volume":"19","author":"Chatterjee","year":"2023","journal-title":"Alzheimer\u2019s Dementia"},{"key":"B28","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13195-024-01503-x","article-title":"Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers","volume":"16","author":"Ordu\u00f1a Dolado","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.3390\/brainsci11101352","article-title":"Mental illness and amyloid: A scoping review of scientific evidence over the last 10 years (2011 to 2021)","volume":"11","author":"Pandolfo","year":"2021","journal-title":"Brain Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1212\/WNL.0b013e31823ed0f0","article-title":"Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort","volume":"78","author":"Schoonenboom","year":"2012","journal-title":"Neurology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadm.2017.04.007","article-title":"Consensus guidelines for lumbar puncture in patients with neurological diseases","volume":"8","author":"Engelborghs","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated Tau 217 immunoassay for Alzheimer disease pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.13855","article-title":"Blood biomarkers to detect Alzheimer disease in primary care and secondary care","volume":"332","author":"Palmqvist","year":"2024","journal-title":"JAMA"},{"key":"B34","doi-asserted-by":"crossref","DOI":"10.1101\/2024.04.29.24306586","volume-title":"Diagnostic utility of plasma ptau217, ptau181, GFAP for Alzheimer disease in a heterogeneous younger onset dementia clinical cohort","author":"Eratne","year":"2024"},{"key":"B35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jamaneurol.2023.4596","article-title":"Plasma biomarker strategy for selecting patients with Alzheimer disease for antiamyloid immunotherapies","volume":"81","author":"Mattsson-Carlgren","year":"2024","journal-title":"JAMA Neurol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/00048674231187312","article-title":"Plasma neurofilament light in behavioral variant frontotemporal dementia compared to mood and psychotic disorders","volume":"58","author":"Eratne","year":"2024","journal-title":"Aust New Z J Psychiatry"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14278","article-title":"Plasma and CSF neurofilament light chain distinguish neurodegenerative from primary psychiatric conditions in a clinical setting","author":"Eratne","year":"2024","journal-title":"Alzheimers Dement"},{"key":"B38","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s43587-023-00404-2","article-title":"Towards a future where Alzheimer's disease pathology is stopped before the onset of dementia","volume":"3","author":"van der Flier","year":"2023","journal-title":"Nat Aging"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2024.1488494\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T14:40:45Z","timestamp":1733409645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2024.1488494\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":38,"alternative-id":["10.3389\/fpsyt.2024.1488494"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2024.1488494","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"article-number":"1488494"}}